Locally produced specific cytomegalovirus immunoglobulin for intramuscular use as a therapy in renal allograft recipients.
Immunomodulator, i.e. specific hyperimmune anticytomegalovirus immunoglobulin for intramuscular administration, produced in 1999 with the aim of prevention of CMVI, and the development of the disease, was for the first time applied in kidney transplant recipients in January 2000, in the Center for kidney transplantation at the Military Medical Academy. Therapy was administered in four cytomegalovirus (CMV)--seronegative kidney recipients from CMV-seropositive donors--the combination that in the majority of cases lead to the development of CMVI/disease resulting in transplant rejection. Patients received 0.2-0.3 ml/kg of cytomegalovirus immunoglobulin (CMVIG) 6 hours before the transplantation, and subsequently the same dose during the following 5 weeks. Simultaneously, they received ganciclovir in therapeutic doses adjusted according to creatine clearance during the first three post-transplantation months (2 weeks parenterally, the rest orally). Kidney transplant recipients tolerated well i.m. applied CMVIG without any adverse effects. Test result obtained from the Paul-Erlich Institute, Germany in 1999 spoke in favor of the quality of the first national CMVIG preparation.
Trkuljić
M
M
Military Medical Academy, Institute of Transfusiology, Dedinje, Belgrade.
Ignjatović
L
L
Hrvacević
R
R
Taseski
J
J
Dujić
A
A
Jovanović
D
D
Kuljić-Kapulica
N
N
D000914:Antibodies, Viral / Q000097:blood; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006801:Humans; D007116:Immunization, Passive; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D007273:Injections, Intramuscular; D016030:Kidney Transplantation / Q000276:immunology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G